The effectiveness of influenza vaccination in preventing hospitalizations in elderly in Beijing, 2016-18

Daitao Zhang; Yi Zhang; Quanyi Wang; Jerome Lock; Yang Pan; Shujuan Cui; Peng Yang; Yonghua Hu

doi:10.1016/j.vaccine.2019.02.013

The effectiveness of influenza vaccination in preventing hospitalizations in elderly in Beijing, 2016-18

Daitao Zhang, Yi Zhang, Quanyi Wang, Jerome Lock, Yang Pan, Shujuan Cui, Peng Yang, Yonghua Hu^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background: Influenza vaccinations play an important role in preventing influenza related hospitalizations. The objective of this study was to estimate the effectiveness of vaccination in protecting Beijing residents aged >= 60 years from influenza related hospitalizations during the 2016/17 and 2017/18 influenza seasons.

Methods: Patients who met the definition of severe acute respiratory infection (SARI) and were hospitalized in the nine sentinel hospitals in Beijing during the 2016/17 and 2017/18 influenza seasons were identified as the study population. The vaccination status of patients was obtained from a vaccination registry. Real-time reverse transcription polymerase chain reaction (RT-PCR) experiments were conducted to test pharyngeal or lower respiratory tract samples collected from SARI patients for influenza A and B viruses. Vaccine effectiveness (VE) was examined using a test-negative design that compare the odds of vaccination among influenza positives and negatives, adjusting for calendar week of illness onset, age, and underlying medical conditions.

Results: We identified 50,364 patients in the study, in which there were 145 influenza cases and 528 influenza-negative controls aged >= 60 years in 2016/17 season and 149 cases and 358 controls aged >= 60 years in 2017/18 season. The most commonly identified subtype among participants was influenza A(H3N2) in 2016/17 and 2017/18 season (78.5% and 70.6%). Among the adults aged >= 60 years, the adjusted VE of vaccination against any influenza virus for serious acute respiratory infection (SARI) patients was 32.8% (95% confidence interval ICI]: -22.0 to 63.0%) in 2016/17 season. While the adjusted VE in 2017/18 season were 4.6% (95% CI: -72.4 to 47.2%) against any types of influenza, 29.2% (95% CI: -92.9 to 74%) against influenza A(H1N1)pdm09, -37.7% (95% Cl: -293.8; 51.9%) against influenza A (H3N2) viruses, and 3.6% (95% CI: -113.8 to 56.5%) against influenza B.

Conclusion: The influenza vaccine provided moderate protection in 2016/17 season and mild protection in 2017/18 season for influenza related inpatients of adults aged >= 60 years in Beijing. (C) 2019 Published by Elsevier Ltd.

Original language	English
Pages (from-to)	1853-1858
Number of pages	6
Journal	Vaccine
Volume	37
Issue number	13
DOIs	https://doi.org/10.1016/j.vaccine.2019.02.013
Publication status	Published - 22 Mar 2019

Keywords

Influenza
Vaccine effectiveness
Test-negative
Hospitalization
SEASONAL INFLUENZA
UNITED-STATES
CHINA
PROTECTION
A(H3N2)
VIRUSES

Access to Document

10.1016/j.vaccine.2019.02.013

Cite this

@article{99794ae6675e4371a26d61a461e5a2b3,

title = "The effectiveness of influenza vaccination in preventing hospitalizations in elderly in Beijing, 2016-18",

abstract = "Background: Influenza vaccinations play an important role in preventing influenza related hospitalizations. The objective of this study was to estimate the effectiveness of vaccination in protecting Beijing residents aged >= 60 years from influenza related hospitalizations during the 2016/17 and 2017/18 influenza seasons.Methods: Patients who met the definition of severe acute respiratory infection (SARI) and were hospitalized in the nine sentinel hospitals in Beijing during the 2016/17 and 2017/18 influenza seasons were identified as the study population. The vaccination status of patients was obtained from a vaccination registry. Real-time reverse transcription polymerase chain reaction (RT-PCR) experiments were conducted to test pharyngeal or lower respiratory tract samples collected from SARI patients for influenza A and B viruses. Vaccine effectiveness (VE) was examined using a test-negative design that compare the odds of vaccination among influenza positives and negatives, adjusting for calendar week of illness onset, age, and underlying medical conditions.Results: We identified 50,364 patients in the study, in which there were 145 influenza cases and 528 influenza-negative controls aged >= 60 years in 2016/17 season and 149 cases and 358 controls aged >= 60 years in 2017/18 season. The most commonly identified subtype among participants was influenza A(H3N2) in 2016/17 and 2017/18 season (78.5% and 70.6%). Among the adults aged >= 60 years, the adjusted VE of vaccination against any influenza virus for serious acute respiratory infection (SARI) patients was 32.8% (95% confidence interval ICI]: -22.0 to 63.0%) in 2016/17 season. While the adjusted VE in 2017/18 season were 4.6% (95% CI: -72.4 to 47.2%) against any types of influenza, 29.2% (95% CI: -92.9 to 74%) against influenza A(H1N1)pdm09, -37.7% (95% Cl: -293.8; 51.9%) against influenza A (H3N2) viruses, and 3.6% (95% CI: -113.8 to 56.5%) against influenza B.Conclusion: The influenza vaccine provided moderate protection in 2016/17 season and mild protection in 2017/18 season for influenza related inpatients of adults aged >= 60 years in Beijing. (C) 2019 Published by Elsevier Ltd.",

keywords = "Influenza, Vaccine effectiveness, Test-negative, Hospitalization, SEASONAL INFLUENZA, UNITED-STATES, CHINA, PROTECTION, A(H3N2), VIRUSES",

author = "Daitao Zhang and Yi Zhang and Quanyi Wang and Jerome Lock and Yang Pan and Shujuan Cui and Peng Yang and Yonghua Hu",

note = "Funding Information: This work was supported by the Capital's Funds for Health Improvement and Research (grant number 2018-2-1013). Publisher Copyright: {\textcopyright} 2019",

year = "2019",

month = mar,

day = "22",

doi = "10.1016/j.vaccine.2019.02.013",

language = "English",

volume = "37",

pages = "1853--1858",

journal = "Vaccine",

issn = "0264-410X",

publisher = "ELSEVIER SCI LTD",

number = "13",

}

TY - JOUR

T1 - The effectiveness of influenza vaccination in preventing hospitalizations in elderly in Beijing, 2016-18

AU - Zhang, Daitao

AU - Zhang, Yi

AU - Wang, Quanyi

AU - Lock, Jerome

AU - Pan, Yang

AU - Cui, Shujuan

AU - Yang, Peng

AU - Hu, Yonghua

PY - 2019/3/22

Y1 - 2019/3/22

N2 - Background: Influenza vaccinations play an important role in preventing influenza related hospitalizations. The objective of this study was to estimate the effectiveness of vaccination in protecting Beijing residents aged >= 60 years from influenza related hospitalizations during the 2016/17 and 2017/18 influenza seasons.Methods: Patients who met the definition of severe acute respiratory infection (SARI) and were hospitalized in the nine sentinel hospitals in Beijing during the 2016/17 and 2017/18 influenza seasons were identified as the study population. The vaccination status of patients was obtained from a vaccination registry. Real-time reverse transcription polymerase chain reaction (RT-PCR) experiments were conducted to test pharyngeal or lower respiratory tract samples collected from SARI patients for influenza A and B viruses. Vaccine effectiveness (VE) was examined using a test-negative design that compare the odds of vaccination among influenza positives and negatives, adjusting for calendar week of illness onset, age, and underlying medical conditions.Results: We identified 50,364 patients in the study, in which there were 145 influenza cases and 528 influenza-negative controls aged >= 60 years in 2016/17 season and 149 cases and 358 controls aged >= 60 years in 2017/18 season. The most commonly identified subtype among participants was influenza A(H3N2) in 2016/17 and 2017/18 season (78.5% and 70.6%). Among the adults aged >= 60 years, the adjusted VE of vaccination against any influenza virus for serious acute respiratory infection (SARI) patients was 32.8% (95% confidence interval ICI]: -22.0 to 63.0%) in 2016/17 season. While the adjusted VE in 2017/18 season were 4.6% (95% CI: -72.4 to 47.2%) against any types of influenza, 29.2% (95% CI: -92.9 to 74%) against influenza A(H1N1)pdm09, -37.7% (95% Cl: -293.8; 51.9%) against influenza A (H3N2) viruses, and 3.6% (95% CI: -113.8 to 56.5%) against influenza B.Conclusion: The influenza vaccine provided moderate protection in 2016/17 season and mild protection in 2017/18 season for influenza related inpatients of adults aged >= 60 years in Beijing. (C) 2019 Published by Elsevier Ltd.

AB - Background: Influenza vaccinations play an important role in preventing influenza related hospitalizations. The objective of this study was to estimate the effectiveness of vaccination in protecting Beijing residents aged >= 60 years from influenza related hospitalizations during the 2016/17 and 2017/18 influenza seasons.Methods: Patients who met the definition of severe acute respiratory infection (SARI) and were hospitalized in the nine sentinel hospitals in Beijing during the 2016/17 and 2017/18 influenza seasons were identified as the study population. The vaccination status of patients was obtained from a vaccination registry. Real-time reverse transcription polymerase chain reaction (RT-PCR) experiments were conducted to test pharyngeal or lower respiratory tract samples collected from SARI patients for influenza A and B viruses. Vaccine effectiveness (VE) was examined using a test-negative design that compare the odds of vaccination among influenza positives and negatives, adjusting for calendar week of illness onset, age, and underlying medical conditions.Results: We identified 50,364 patients in the study, in which there were 145 influenza cases and 528 influenza-negative controls aged >= 60 years in 2016/17 season and 149 cases and 358 controls aged >= 60 years in 2017/18 season. The most commonly identified subtype among participants was influenza A(H3N2) in 2016/17 and 2017/18 season (78.5% and 70.6%). Among the adults aged >= 60 years, the adjusted VE of vaccination against any influenza virus for serious acute respiratory infection (SARI) patients was 32.8% (95% confidence interval ICI]: -22.0 to 63.0%) in 2016/17 season. While the adjusted VE in 2017/18 season were 4.6% (95% CI: -72.4 to 47.2%) against any types of influenza, 29.2% (95% CI: -92.9 to 74%) against influenza A(H1N1)pdm09, -37.7% (95% Cl: -293.8; 51.9%) against influenza A (H3N2) viruses, and 3.6% (95% CI: -113.8 to 56.5%) against influenza B.Conclusion: The influenza vaccine provided moderate protection in 2016/17 season and mild protection in 2017/18 season for influenza related inpatients of adults aged >= 60 years in Beijing. (C) 2019 Published by Elsevier Ltd.

KW - Influenza

KW - Vaccine effectiveness

KW - Test-negative

KW - Hospitalization

KW - SEASONAL INFLUENZA

KW - UNITED-STATES

KW - CHINA

KW - PROTECTION

KW - A(H3N2)

KW - VIRUSES

U2 - 10.1016/j.vaccine.2019.02.013

DO - 10.1016/j.vaccine.2019.02.013

M3 - Article

SN - 0264-410X

VL - 37

SP - 1853

EP - 1858

JO - Vaccine

JF - Vaccine

IS - 13

ER -